The first-line treatment regimen of PD-1 monoclonal antibody combined with chemotherapy or HER2 monoclonal antibody were found to improve the survival and effective rate of HER2-negative gastric cancer patients. The gene discussed is ERBB2; the disease is gastric cancer.